Reduce freezing episodes during walking
- Trial ID
- NCT06630702
- Official Title
- Application of Thoracic Epidural Spinal Cord Stimulation (SCS) for Managing Freezing of Gait (FOG) in Patients With Advanced Parkinson's Disease
- Goal
- Reduce freezing episodes during walking
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- National Taiwan University Hospital
- Study Type
- INTERVENTIONAL
- Enrollment
- 5 participants
- Conditions
- Parkinson Disease, Freezing of Gait, Spinal Cord Stimulation
- Interventions
- SCS electrode stimulation 1, SCS electrode stimulation 2, SCS electrode stimulation 3
Plain-Language Summary
The goal is to reduce freezing of gait in people with advanced Parkinson's who still respond to medication but keep having walking freezes that drugs do not stop. The approach is thoracic epidural spinal cord stimulation, which places electrodes in the upper back epidural space to send mild electrical pulses to spinal cord pathways that help coordinate walking. The stimulation aims to normalize gait-related signals so freezes happen less often or are shorter, it does not replace levodopa and can be used alongside your current medications. The trial is looking for adults 40 to 85 years old with Parkinson's for more than 5 years, clear drug response but persistent medication-resistant freezing, and no atypical Parkinsonism, major spinal problems, uncontrolled bleeding risk, or severe dementia.
Locations
- National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Hsinchu City, Taiwan
Frequently Asked Questions
- What is this trial testing?
- This trial is studying SCS electrode stimulation 1. The goal is to reduce freezing of gait in people with advanced Parkinson's who still respond to medication but keep having walking freezes that drugs do not stop. The approach is thoracic epidural spinal cord stimulation, which places electrodes in the upper back epidural space to send mild electrical pulses to spinal cord pathways that help coordinate walking. The stimulation aims to normalize gait-related signals so freezes happen less often or are shorter, it does not replace levodopa and can be used alongside your current medications. The trial is looking for adults 40 to 85 years old with Parkinson's for more than 5 years, clear drug response but persistent medication-resistant freezing, and no atypical Parkinsonism, major spinal problems, uncontrolled bleeding risk, or severe dementia.
- Who can participate?
- Participants must be between 40 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 3 months.